Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

4 Cutting-Edge Pharma Stocks for Portfolio Diversification

The pharmaceutical industry is expected to grow rapidly due to increasing healthcare demand, technological advancements, and rising demand for innovative drugs. Therefore, for portfolio diversification, investors could consider buying fundamentally strong pharmaceutical stocks such as Bayer (BAYRY), Procaps Group (PROC), ACADIA Pharmaceuticals (ACAD), and Zoetis (ZTS). Read more.

StockNews.com

Many pharma companies that bought electoral bonds faced regulatory actions

Top pharmaceutical companies purchased electoral bonds amidst regulatory scrutiny, including Hetero, MSN, Divi's, Intas, Lupin, Mankind, Micro Labs, and Natco.

The Hindu

3 Pharma Stocks Fueling Investor Enthusiasm

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Top 3 Pharma Innovators to Watch Closely

The pharmaceutical industry is experiencing considerable growth, driven by rising healthcare needs, continuous advances in drug discovery & discovery, and M&A activity. So, investors could keep a close eye on top pharma stocks Amneal Pharmaceuticals (AMRX), Collegium Pharmaceutical (COLL), and Sanofi (SNY) for potential gains. Keep reading….

StockNews.com

Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst

Abbott stock tumbled to a month-low Friday after an Illinois jury ordered Reckitt Benckiser to pay $60 million in an infant formula lawsuit.

Investors Business Daily

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

StockNews.com

3 B-Rated Biotech Stocks to Boost Your Bottom Line

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Jumpstart Your Portfolio Gains

The biotech industry is poised for robust growth due to increasing demand for personalized treatments, rising prevalence of chronic diseases, heightened investments in R&D, and advancements in technology. Therefore, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), ANI Pharmaceuticals (ANIP), and United Therapeutics (UTHR). Read more.

StockNews.com

Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test

Moderna stock surged Monday, nearing its first breakout in over a year, after launching a third study of its cancer vaccine.

Investors Business Daily

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.

Investors Business Daily

US pharma group opposing abortion pill restrictions also backs Republicans attacking drug

Group advocating to preserve FDA judgment in supreme court case also gave $125,000 to Republicans opposing mifepristone

The Guardian - US

Biden Spotlights Drug Prices, Medicare, Social Security in State of the Union

Biden calls for expanding Medicare drug price negotiations to include up to 500 drugs over next decade.

Kiplinger

Chemicals Giant Bayer Rules Out Break-up 'For Now' After Huge Loss

CEO Bill Anderson, hired last year to help steer the troubled group in a new direction, ruled out any imminent break-up of the company -- despite mounting pressure from activist investors.

International Business Times

Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy

Top-notch biotech stock Avidity tumbled Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug

Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. But BridgeBio stock tumbled Monday.

The Hindu

Supreme Court’s ban on Patanjali ads | Explained

The Bench also issued a contempt notice against the company and its Managing Director Acharya Balkrishna for failing to adhere to directions passed in November last year. The “entire country has been taken for a ride”, the Bench said, while reprimanding the Union Government for its failure to take “urgent…

WEKU

CVS and Walgreens to start dispensing abortion pill in states where it's legal

CVS will start filling prescriptions for mifepristone in Massachusetts and Rhode Island. Walgreens will start in New York, Pennsylvania, Massachusetts, California and Illinois.

The Guardian - US

Two of biggest US pharmacy chains to stock mifepristone abortion pill

Biden applauds decision by CVS and Walgreens to offer drug on prescription at stores in several US states where abortion is legal

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

The Guardian - UK

GlaxoSmithKline boss’s pay package jumps 50% to £12.7m

Emma Walmsley’s deal, with a high share bonus payout, makes her one of top-paid CEOs in FTSE 100

StockNews.com

3 Pharma Stocks With Prescription for Stability and Value in March

Amid rising healthcare demand globally, advancements in precision medicine, and the booming e-pharmacy market, the pharmaceutical industry is expected to witness significant long-term growth. Hence, fundamentally sound pharma stocks Dr. Reddy’s Laboratories (RDY), Ipsen (IPSEY), and Johnson & Johnson (JNJ), which boast low beta values and attractive valuation metrics, might…

Investors Business Daily

Ironwood Pharmaceuticals Ran Up 38% Over Three Months — And Just Lost It All

Shares of Ironwood Pharmaceuticals collapsed Thursday on mixed results for its gastrointestinal drug. The biotech stock erased a 38% gain.

StockNews.com

3 Pharma Stocks to Consider for March Gains

The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest in quality pharma stocks Perrigo (PRGO), OptiNose (OPTN), and Teva Pharmaceutical (TEVA) for solid gains. Keep reading….

StockNews.com

3 Biotech Stocks to Watch in March for Success

The biotech industry is set for strong growth amid the growing need for personalized treatments, the rising number of chronic diseases, increased investment in research, and the use of advanced technologies. Therefore, investors could consider adding fundamentally strong biotech stocks Acorda Therapeutics (ACOR), BioNTech (BNTX), and Jazz Pharmaceuticals (JAZZ) to…

Investors Business Daily

TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?

TG Therapeutics shares soared Wednesday after sales of its multiple sclerosis treatment met expectations. TGTX stock topped its 200-day line.

1 … 22 23 24 25

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.